Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative.
Open Access
- 1 May 1992
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 89 (5), 1618-1621
- https://doi.org/10.1172/jci115757
Abstract
Oxidative modification of low density lipoprotein (LDL) renders it more atherogenic. Probucol, a highly nonpolar antioxidant, is transported in lipoproteins, including LDL, and inhibits oxidative modification of LDL in vitro. The ability of probucol to inhibit atherogenesis in the LDL receptor-deficient rabbit has been attributed to its antioxidant effect. We report synthesis of a new water-soluble analogue of probucol that is very effective in preventing cell-induced LDL oxidation. The polar probucol derivative, diglutaryl probucol, is efficiently taken up by endothelial cells and macrophages in culture and is hydrolyzed to release the active antioxidant, probucol. The treated cells, after thorough washing, show a marked decrease in their capacity to oxidize LDL during a subsequent incubation. At high concentrations of the derivative, the cells also released free probucol into the medium. Thus, the effectiveness of probucol in vivo may be related both to its presence in LDL, acting as a nonspecific antioxidant, and to an additional ability to inhibit cell-mediated oxidation of LDL by virtue of its uptake into cells.This publication has 16 references indexed in Scilit:
- Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophagesJournal of Lipid Research, 1991
- Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions.Proceedings of the National Academy of Sciences, 1990
- ProbucolDrugs, 1989
- A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein.Proceedings of the National Academy of Sciences, 1989
- Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modificationJournal of Lipid Research, 1988
- Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.Proceedings of the National Academy of Sciences, 1987
- Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1986
- Probucol inhibits oxidative modification of low density lipoprotein.Journal of Clinical Investigation, 1986
- Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids.Proceedings of the National Academy of Sciences, 1984
- INVITRO STUDIES ON THE DISTRIBUTION OF PROBUCOL AMONG HUMAN-PLASMA LIPOPROTEINS1984